Angioplasty-induced Rupture Research Articles

Percutaneous Salvage of Thrombosed Immature Arteriovenous Fistulas

Thrombosed immature fistulas have historically been considered unsalvageable. However, advances in procedure and balloon catheter technologies have expanded the scope of endovascular treatments. This study investigates the efficacy, functionality, and cost associated with the use of percutaneous techniques for the salvage of thrombosed immature fistulas. Over a 2-year period and from a population of 18,000 patients on hemodialysis, 140 consecutive patients with thrombosed immature fistulas underwent attempts at salvage via thrombectomy procedures. All fistulas had thrombosed following access creation and had never been used for hemodialysis. Multiple approaches were utilized to gain access to the fistula, including trans-fistula cannulation, distal arterial puncture, and proximal retrograde venous access. Thrombectomy was performed via balloon maceration and aspiration. Accelerated maturation was achieved through sequential angioplasty of diffusely stenotic veins and elimination of competing branch vessels. Primary access, primary assisted, and secondary access patencies were calculated at 3, 6, 12, and 24 months. A cost analysis was performed based on procedure statistics and the 2009 Medicare reimbursement schedule and compared with data from the 2009 United States Renal Data Survey. Thrombectomy was successful in 119 (85%) immature clotted fistulas, and hemodialysis adequacy was achieved in 111 (79%) fistulas. The average maturation time from thrombectomy to cannulation for dialysis was 46.4 days, with an average of 2.64 interventions per patient. There were 5 (3.5%) cases of angioplasty-induced rupture, all of which were treated with stent placement. Clinically significant pseudoaneurysm formation occurred in 4 (2.8%) patients. At 12 months, secondary access patency of salvaged accesses was 90%. Based on 2009 Medicare outpatient billing rates per patient per initial access-year and the maturation times observed in the New York area, percutaneous salvage of thrombosed immature fistulas costs $4881 to $14,998 less than access abandonment and new access creation. Endovascular techniques can be used for the salvage of thrombosed nonmaturing fistulas. When analyzed within the initial access-year, this approach yields significant cost savings over access abandonment.

Complications Related to Percutaneous Thrombectomy of Hemodialysis Grafts

To retrospectively review the complications reported during percutaneous thrombectomy procedures performed on polytetrafluoroethylene hemodialysis grafts. A retrospective review revealed that 935 percutaneous thrombectomy procedures were performed at our institution between January 1993 and June 2001. The type and number of procedures include: Arrow PTD (527), pulse-spray with urokinase (240), Amplatz Thrombectomy Device (96), AngioJet (17), Oasis (15), Hydrolyser (10), Endovac (7), Lyse and Wait (7), Thrombex (6), Cragg brush (6), Castaneda brush (4). Complications were reported to have occurred in 31 patients. The radiology reports and medical records of these patients were reviewed. The overall complication rate was 3.3%. The type and number of complications included: rupture of a vein during angioplasty (13), severe cardiopulmonary distress (4), arterial emboli (4), rigors related to urokinase (3), minor bleeding (2), hypoxia with chest pain (2), other assorted complications (3). There was one death resulting from a fall from the angiography table immediately following the procedure. There were 12 minor complications, requiring minimal treatment, and 19 major complications that altered the course of the procedure or treatment of the patient. The most common complication was angioplasty-induced rupture of the vein or graft. The most severe complications occurred immediately following dislodgement of the arterial plug and were likely due to acute pulmonary embolization.

Endovascular Stent Placement for Angioplasty-induced Venous Rupture Related to the Treatment of Hemodialysis Grafts

To assess the use of endovascular stents for treating rupture after percutaneous transluminal angioplasty (PTA) in the maintenance of hemodialysis grafts. From February 1, 1994, to August 1, 1997, 683 hemodialysis-related angioplasty procedures were performed on 277 patients to treat thrombosed or poorly functioning polytetrafluoroethylene (PTFE) hemodialysis bridge grafts. In each of these procedures, angioplasty of the venous anastomosis or the outflow vein was performed. This study is a retrospective review to analyze uncovered endovascular stents placed to treat ruptures after PTA. Fourteen ruptures were treated with use of an uncovered metal stent. Stent placement was technically successful in 11 of 14 patients, with clinical success in 11 of 14 cases. The primary patencies at 30, 60, 90, and 120 days were calculated by means of Kaplan-Meier life-table analysis; these were 63%, 54%, 46%, and 46%, respectively. The secondary patencies at 60, 120, and 180 days were 85%, 75%, and 75%, respectively. No complications were attributable to stent placement. The results are comparable to those of stents placed for reasons other than rupture, and support the efficacy of their use for this indication. Endovascular stent placement is a safe and effective means of salvaging angioplasty-induced rupture that occurs during the treatment of hemodialysis grafts.

Wallstents and Craggstents in Hemodialysis Grafts and Fistulas: Results for Selective Indications

To report the value of selective placement of self-expandable stents (Wallstent and Craggstent) for the treatment of limitations and, occasionally, of complications of dilation in hemodialysis access, and especially for delaying restenosis. This is a retrospective study of a 7-year period, during which 41 Wallstents and 11 Craggstents were placed in 26 polytetrafluoroethylene (PTFE) grafts, 15 native fistulas, and nine central veins of 47 patients. The indications were stenosis recoil (n = 13), recurrent restenosis within 6 months (n = 33), restenosis after 6 months (n = 3), and acute angioplasty-induced rupture (n = 1). Restenosis after stent placement necessitated redilation and percutaneous declotting and 10 additional stent placements. Two initial misplacements were corrected immediately. Primary patency rates for PTFE grafts were 58% +/- 10% at 6 months and 23% +/- 10% at 1 year, respectively. Secondary patency rates were 100% at 6 months and 88% +/- 8% at 1 year, respectively. For native fistulas, primary patency rates were 47% +/- 12% at 6 months and 20% +/- 18% at 1 year. Secondary patency rates were 95% +/- 6% at 6 months and 79% +/- 14% at 1 year. It was necessary to reintervene after stent placement to maintain or to restore patency every 9 months for PTFE grafts and every 7.3 months for native fistulas. When stents were placed for treatment of early recurring restenosis, the mean interval between radiologic interventions (redilations or declottings) performed to maintain or to restore patency before stent placement was multiplied by 2.1 after stent placement for both grafts (3.2 months increased to 6.9, P < .01) and native fistulas (2.9 months increased to 6.2, P < .02). Wallstents and Craggstents are valuable for the treatment of failure of regular dilation and they double the intervals between reinterventions for early (< 6 months) recurring stenoses in PTFE grafts and native fistulas.